CU23860B1 - Sales de n-[6-(cis-2,6-dimetil-morfolin-4-il)-piridin-3-il]-2-metil-4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida - Google Patents

Sales de n-[6-(cis-2,6-dimetil-morfolin-4-il)-piridin-3-il]-2-metil-4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida

Info

Publication number
CU23860B1
CU23860B1 CU2011000055A CU20110055A CU23860B1 CU 23860 B1 CU23860 B1 CU 23860B1 CU 2011000055 A CU2011000055 A CU 2011000055A CU 20110055 A CU20110055 A CU 20110055A CU 23860 B1 CU23860 B1 CU 23860B1
Authority
CU
Cuba
Prior art keywords
trifluoro
cis
salts
bifenil
carboxamida
Prior art date
Application number
CU2011000055A
Other languages
English (en)
Other versions
CU20110055A7 (es
Inventor
Joginder S Bajwa
La Cruz Marilyn De
Stephanie Kay Dodd
Liladhar Murlidhar Waykole
Raeann Wu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41228716&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU23860(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20110055A7 publication Critical patent/CU20110055A7/es
Publication of CU23860B1 publication Critical patent/CU23860B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se preparan y se caracterizan sales de N-[6-(cis-2,6-dimetil-morfolin-4-il)-piridin-3-il]-2-2metil-4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida. ESPACIO PARA LA FÓRMULA
CU2011000055A 2008-09-17 2011-03-15 Sales de n-[6-(cis-2,6-dimetil-morfolin-4-il)-piridin-3-il]-2-metil-4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida CU23860B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9758008P 2008-09-17 2008-09-17
PCT/US2009/056918 WO2010033481A1 (en) 2008-09-17 2009-09-15 Salts of n-[6-cis-2,6-dimethylmorpholin-4yl)pyridine-3yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide

Publications (2)

Publication Number Publication Date
CU20110055A7 CU20110055A7 (es) 2011-12-28
CU23860B1 true CU23860B1 (es) 2013-02-26

Family

ID=41228716

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2011000055A CU23860B1 (es) 2008-09-17 2011-03-15 Sales de n-[6-(cis-2,6-dimetil-morfolin-4-il)-piridin-3-il]-2-metil-4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida

Country Status (39)

Country Link
US (3) US8063043B2 (es)
EP (1) EP2342198B1 (es)
JP (2) JP4897938B2 (es)
KR (2) KR20120015363A (es)
CN (1) CN102159570B (es)
AR (2) AR073591A1 (es)
AU (1) AU2009293444B2 (es)
BR (2) BR122020009045B1 (es)
CA (1) CA2736751C (es)
CL (1) CL2011000551A1 (es)
CO (1) CO6351744A2 (es)
CR (1) CR20110126A (es)
CU (1) CU23860B1 (es)
DK (1) DK2342198T3 (es)
DO (1) DOP2011000082A (es)
EA (1) EA020048B1 (es)
EC (1) ECSP11010985A (es)
ES (1) ES2418485T3 (es)
GE (1) GEP20125592B (es)
HN (1) HN2011000745A (es)
HR (1) HRP20130597T1 (es)
IL (1) IL211412A (es)
JO (1) JO2889B1 (es)
MA (1) MA32717B1 (es)
MX (1) MX2011002805A (es)
MY (1) MY151100A (es)
NI (1) NI201100051A (es)
NZ (1) NZ591420A (es)
PE (1) PE20110292A1 (es)
PH (1) PH12012500399A1 (es)
PL (1) PL2342198T3 (es)
PT (1) PT2342198E (es)
SI (1) SI2342198T1 (es)
SM (1) SMT201300072B (es)
SV (1) SV2011003857A (es)
TW (1) TWI367883B (es)
UA (1) UA103049C2 (es)
WO (1) WO2010033481A1 (es)
ZA (1) ZA201101579B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
CN101993415B (zh) * 2010-09-15 2013-08-14 北京韩美药品有限公司 作为Hedgehog通路抑制剂的化合物以及包含该化合物的药物组合物及其应用
ES2935528T3 (es) * 2013-02-25 2023-03-07 Sun Pharmaceutical Ind Ltd Formulación y suspensión oral de un fármaco oncológico
WO2015092720A1 (en) * 2013-12-19 2015-06-25 Novartis Ag Metabolites of sonidegib (lde225)
WO2016155630A1 (zh) * 2015-03-30 2016-10-06 苏州晶云药物科技有限公司 N-[6-(顺式-2,6-二甲基吗啉-4-基)吡啶-3-基]-2-甲基-4'-(三氟甲氧基)[1,1'-联苯]-3-甲酰胺单磷酸盐的晶型及其制备方法
HRP20251395T1 (hr) 2015-06-04 2026-02-13 Sol-Gel Technologies Ltd. Topikalne formulacije za isporuku spojeva inhibitora hedgehog signalnog puta i njihova uporaba
ES3057783T3 (en) 2016-03-15 2026-03-04 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
WO2017163258A1 (en) * 2016-03-22 2017-09-28 Msn Laboratories Private Limited Process for the preparation of n-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2- methyl-4'-(trifiuoromethoxy) [1,1' -biphenyi]-3-carboxamide and its polymorphs thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06003661A (es) * 2003-10-02 2006-06-05 Pharmacia & Upjohn Co Llc Sales y polimorfos de un compuesto de indolinona sustituido con pirrol.
GB0412468D0 (en) * 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
UA93548C2 (uk) 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
PE20080948A1 (es) * 2006-07-25 2008-09-10 Irm Llc Derivados de imidazol como moduladores de la senda de hedgehog

Also Published As

Publication number Publication date
SV2011003857A (es) 2011-05-16
BR122020009045A2 (pt) 2020-11-10
BRPI0918629A2 (pt) 2020-10-27
US20120214810A1 (en) 2012-08-23
JP2012097104A (ja) 2012-05-24
EP2342198A1 (en) 2011-07-13
CL2011000551A1 (es) 2011-07-15
DOP2011000082A (es) 2011-04-15
EA201100501A1 (ru) 2011-10-31
KR101129088B1 (ko) 2012-03-23
TWI367883B (en) 2012-07-11
KR20110056325A (ko) 2011-05-26
PH12012500399A1 (en) 2014-04-28
CO6351744A2 (es) 2011-12-20
MX2011002805A (es) 2011-04-11
UA103049C2 (uk) 2013-09-10
IL211412A (en) 2014-07-31
HK1156628A1 (en) 2012-06-15
BRPI0918629B8 (pt) 2021-05-25
CA2736751A1 (en) 2010-03-25
ES2418485T3 (es) 2013-08-14
BRPI0918629B1 (pt) 2021-04-13
JP2012502912A (ja) 2012-02-02
MA32717B1 (fr) 2011-10-02
HRP20130597T1 (en) 2013-07-31
NZ591420A (en) 2012-07-27
NI201100051A (es) 2011-09-08
PL2342198T3 (pl) 2013-08-30
AU2009293444A1 (en) 2010-03-25
US20120035174A1 (en) 2012-02-09
DK2342198T3 (da) 2013-07-01
WO2010033481A1 (en) 2010-03-25
ECSP11010985A (es) 2011-05-31
TW201016686A (en) 2010-05-01
AU2009293444B2 (en) 2012-03-15
BR122020009045B1 (pt) 2022-08-02
KR20120015363A (ko) 2012-02-21
CA2736751C (en) 2012-10-23
EA020048B1 (ru) 2014-08-29
CU20110055A7 (es) 2011-12-28
SMT201300072B (it) 2013-09-06
US8063043B2 (en) 2011-11-22
HN2011000745A (es) 2014-01-06
AR073591A1 (es) 2010-11-17
IL211412A0 (en) 2011-05-31
CR20110126A (es) 2011-04-27
PE20110292A1 (es) 2011-05-17
US20110178085A1 (en) 2011-07-21
SI2342198T1 (sl) 2013-07-31
CN102159570B (zh) 2014-01-15
MY151100A (en) 2014-04-15
JO2889B1 (en) 2015-03-15
EP2342198B1 (en) 2013-04-03
ZA201101579B (en) 2011-11-30
PT2342198E (pt) 2013-07-10
AR113778A2 (es) 2020-06-10
JP4897938B2 (ja) 2012-03-14
CN102159570A (zh) 2011-08-17
GEP20125592B (en) 2012-07-25

Similar Documents

Publication Publication Date Title
CU20110055A7 (es) Sales de n-[6-(cis-2,6-dimetil-morfolin-4-il)-piridin-3-il]-2-metil-4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida
CY1123270T1 (el) Υποκατεστημενες ενωσεις βενζαλδεϋδης και μεθοδοι για τη χρηση τους στην αυξηση της οξυγονωσης των ιστων
CR11620A (es) Derivados de Imadazo-[1,2,b]-Piridazina para el Tratamiento de Enfermedad Mediada por Cinosa de Tirosina C-Met
CU20110235A7 (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
CR11241A (es) Compuestos de pirazol y su uso como inhibidores de raf
CO6361936A2 (es) Imidazopiridazinacarbonitrilos utiles como inhibidores de quinasa
BR112014003587A2 (pt) derivados de 5-flúor-4-imino-3-(substituído)-3,4-di-hidropirimidin-2(1h)ona
EA201291409A1 (ru) Производные индолизина, способ их получения и их терапевтическое применение
EA201490596A1 (ru) Новые производные дигидрохинолин-2-она
EA201001124A1 (ru) Производные хинолина и их применение в качестве фунгицидов
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
CU20110220A7 (es) Espiro-epóxidos como productos intermedios
EA201270256A1 (ru) Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида
CU20110113A7 (es) Lactamas como inhibidores beta secretasa
EA201400047A1 (ru) Производные n-оксипиразолотриазиндион
EA201101097A1 (ru) Новые микробиоциды
UY34408A (es) Nuevos moduladores de trpv3
EA201300092A1 (ru) Замещенные производные оксадиазола
EA200800070A1 (ru) Производные 2-(1h-индолилсульфанил)ариламина
AR085909A1 (es) Derivados de azaespirodecanona, composiciones farmaceuticas que los contienen, procedimiento para prepararlos y uso de los mismos para el tratamiento de diabetes, obesidad y enfermedades cardiovasculares, entre otras
EA200901551A1 (ru) Бензамиды, применимые в качестве модуляторов рецептора s1p
UY33862A (es) Nuevos compuestos de benzamida, composiciones agroquímicas que los contienen, procesos de preparación y usos?
FR2977492B1 (fr) Nouvelle association entre le n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl) benzofuran-2-ylcarbonylamino]ethoxy}benzamide et le folfox
AR115996A2 (es) Un proceso para preparar intermediarios de síntesis de compuestos de piridona y aza-piridona y dichos intermediarios

Legal Events

Date Code Title Description
FG Grant of patent